NCT06287268 - Revolade Tablets Specified Drug-use Survey | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 17, 2024

Primary Completion Date

March 28, 2029

Study Completion Date

March 28, 2029

Conditions

Aplastic Anemia

Interventions

OTHER

eltrombopag

This is an observational study. There is no treatment allocation. After confirming that patients are fulfilling the eligibility criteria, patients will be registered in this survey.

Trial Locations (15)

453-8511

RECRUITING

Novartis Investigative Site, Nagoya

466 8560

RECRUITING

Novartis Investigative Site, Nagoya

470 1192

RECRUITING

Novartis Investigative Site, Toyoake

660 8550

RECRUITING

Novartis Investigative Site, Amagasaki

650-0047

RECRUITING

Novartis Investigative Site, Kobe

390-8621

RECRUITING

Novartis Investigative Site, Matsumoto

901-1303

RECRUITING

Novartis Investigative Site, Shimajiri-Gun

594-1101

RECRUITING

Novartis Investigative Site, Izumi

589 8511

RECRUITING

Novartis Investigative Site, Ōsaka-sayama

520-2192

RECRUITING

Novartis Investigative Site, Ohtsu

104 8560

RECRUITING

Novartis Investigative Site, Chuo Ku

143 8541

RECRUITING

Novartis Investigative Site, Ōta-ku

157-8535

RECRUITING

Novartis Investigative Site, Setagaya-ku

534-0021

RECRUITING

Novartis Investigative Site, Osaka

330 8777

RECRUITING

Novartis Investigative Site, Saitama